🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524687-38-00
Completed Phase I

Phase 1/1b Study of RNDO-564 in Participants with Advanced Urothelial Cancer

2025-524687-38-00 · tracked via the Priya Life Science EU tracker
Sponsor
Rondo Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
17/06/2026
Enrollment target
34
Sites
Spain

Condition studied

Other Solid Tumors Associated with Nectin-4 Expression, Relapsed/Refractory Locally Advanced or Metastatic Urothelial Cancer

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524687-38-00 on CTIS ↗ ← All trials in the EU